Live News ›

Anthem Biosciences Share: BUY Rating Aaya, Par Valuation Ka Kya Scene Hai?

BROKERAGE-REPORTS
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Anthem Biosciences Share: BUY Rating Aaya, Par Valuation Ka Kya Scene Hai?
Overview

Arre yaar, Anthem Biosciences (ANTHEM) ke liye ek taraf toh achi khabar hai! Prabhudas Lilladher ne 'BUY' rating de di hai aur target rakha hai ₹755, matlab **16%** tak ka upside ho sakta hai. Lekin dusri taraf, stock ka valuation itna stretched hai ki sab chonk gaye hain!

So, analyst logon ka kehna hai ki Anthem ke pipeline mein dum hai aur company capacity badha rahi hai. Isse revenue 21% CAGR se aur profit 18% CAGR se grow kar sakta hai FY2026 se FY2028 tak. Isi liye target ₹755 diya hai.

Par bhai, asli tension valuation ka hai. Yeh stock abhi 73x P/E aur 13x P/B par trade ho raha hai, jo ki bahut zyada hai. Iska market cap bhi lagbhag ₹38,264 crore ho gaya hai.

Jabki sector mein competitors jaise Divis Laboratories ka P/E 65x ke aas paas hai, aur Syngene International toh aur bhi kam 52x P/E par hai. Laurus Labs bhi hai toh uska bhi P/E 65x ke range mein hai. Anthem ka valuation in sabse zyada stretched lag raha hai.

Aur suno, ek independent analysis karne wali MarketsMojo ne toh isko 'Sell' rating de di hai! Unka kehna hai ki valuation bahut expensive hai aur financial trends bhi theek nahi lag rahe. Stock khud bhi pichhle 52 hafton mein lagbhag 13% gir chuka hai, sector mein boom hone ke baad bhi.

Toh abhi kya karna chahiye? Analysts average target ₹776.60 de rahe hain, matlab 18.34% ka potential upside dikha rahe hain. Lekin yeh sab tabhi hoga jab company apne growth plans execute karegi aur yeh high valuation maintain paayegi. Investors ko soch samajh kar decide karna hoga, kyunki ek taraf bullish view hai aur dusri taraf 'Sell' rating aur expensive valuation ka risk.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.